Search results for "Thromboprophylaxis"
Aspirin for COVID-19 inpatients didn't reduce mortality, trial finds
New data from the RECOVERY trial found a slight reduction in clots but an increase in bleeding and no difference in 28-day mortality in patients randomized to daily aspirin during hospitalization compared to those receiving usual care.
https://acphospitalist.acponline.org/weekly/archives/2021/11/24/2.htm
24 Nov 2021
October 19, 2022
ACP Hospitalist provides hospital-based physicians with news and information about the practice of hospital medicine.
https://acphospitalist.acponline.org/archives/2022/10/19/
New data on tocilizumab, convalescent plasma, anticoagulation for COVID-19
Recent studies found that tocilizumab was potentially harmful for ICU patients, indicated that convalescent plasma works better with higher antibody titers delivered earlier, and offered conflicting findings on anticoagulation. Other research compared mortality from COVID-19 over time.
https://acphospitalist.acponline.org/weekly/archives/2021/01/27/1.htm
27 Jan 2021
January 2012
ACP Hospitalist provides hospital-based physicians with news and information about the practice of hospital medicine.
https://acphospitalist.acponline.org/archives/2012/01/
Mixed news on anticoagulation; new data on myocarditis, postexposure prophylaxis
Full-dose anticoagulation appeared to help hospitalized COVID-19 patients who weren't critically ill but not the critically ill, trials showed. Postvaccine myocarditis and pericarditis were investigated by a study, while new data and an FDA authorization supported postexposure prophylaxis for some patients.
https://acphospitalist.acponline.org/weekly/archives/2021/08/11/1.htm
11 Aug 2021
LMWH may offer best risk-benefit profile for thromboprophylaxis in medical inpatients
A meta-analysis found that an intermediate dose of low-molecular-weight heparin (LMWH) had the most favorable balance of risk and harms during hospitalization for acute illness, while unfractionated heparin and direct oral anticoagulants had the least.
https://acphospitalist.acponline.org/archives/2022/07/13/lmwh-may-offer-best-risk-benefit-profile-for-thromboprophylaxis-in-medical-inpatients.htm
13 Jul 2022
COVID-19 guideline update from NIH, postdischarge anticoagulation, remdesivir effects
The latest news on inpatient COVID-19 care includes some changes to the NIH guidelines for COVID-19 treatment, as well as studies showing that rivaroxaban after discharge reduced clots and remdesivir helped inpatients on no or low-flow oxygen but not those who were sicker.
https://acphospitalist.acponline.org/weekly/archives/2021/12/22/1.htm
22 Dec 2021
Rivaroxaban after discharge may reduce thromboembolic risk in medically ill
An industry-funded trial that gave medical patients rivaroxaban for 45 days after hospital discharge found decreased risk for a composite end point of symptomatic venous thromboembolism, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death compared to placebo.
https://acphospitalist.acponline.org/weekly/archives/2020/06/24/3.htm
24 Jun 2020
Combating clots in COVID-19
Critical care experts advised on appropriate prophylaxis for ward and ICU patients as part of the CHEST 2021 conference.
https://acphospitalist.acponline.org/archives/2021/11/combating-clots-in-covid-19.htm
15 Nov 2021
Compression stockings may be unnecessary for VTE prophylaxis in most patients undergoing elective surgery
In a randomized controlled trial of patients at moderate or high risk of venous thromboembolism (VTE), prophylaxis with low-molecular-weight heparin alone was noninferior to a combination of low-molecular-weight heparin and graduated compression stockings.
https://acphospitalist.acponline.org/weekly/archives/2020/05/20/5.htm
20 May 2020